"name","uuid:ID","id","label","text","description","instanceType"
"OBJ1","377c7246-181c-4f4c-9336-fb8e712a4e12","Objective_1","","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Main objective","Objective"
"OBJ2","a24357ab-f762-4d03-ba7f-5ada483248a6","Objective_2","","To document the safety profile of the xanomeline TTS.","Safety","Objective"
"OBJ3","399d0273-7379-4668-9b0e-190eb396c9f1","Objective_3","","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Behaviour","Objective"
"OBJ4","569f2910-033e-4804-943c-edc9414dc82f","Objective_4","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective"
"OBJ5","e6d18545-48c1-4c82-aed6-f26ab8411067","Objective_5","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective"
"OBJ6","e24293fd-a929-431a-9cfe-b630b7a3bbe4","Objective_6","","To assess the treatment response as a function of Apo E genotype.","","Objective"
